Nozin, Makers of Nozin® Nasal Sanitizer® Antiseptic, Announces Partnership with The Leapfrog Group
BETHESDA, Md. (PRWEB) May 05, 2023 -- Nozin, makers of Nozin® Nasal Sanitizer® antiseptic, today announced its partnership with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on health care safety. John Willimann, CEO of Nozin, will sit on the Leapfrog Partners Advisory Committee.
“The nose is a primary reservoir for pathogens. Nasal decolonization to decrease infection risk is critical to patient safety. For example, hand to nose contact that can spread germs may occur 100 times a day. Nasal decolonization with Nozin® Nasal Sanitizer® has proven to help contain this spread and reduce infection risk significantly,” said John Willimann. "We are thrilled to partner with the Leapfrog Group to expand awareness of daily nasal decolonization as an essential patient safety measure."
“Despite significant efforts to reduce healthcare-associated infections (HAIs), they remain a major safety concern in hospitals across the U.S.,” said Leah Binder, Leapfrog president & CEO. “We know that the nose is a critical source of infection risk, and we are proud to have the leading innovator in nasal decolonization, Nozin, makers of Nozin® Nasal Sanitizer® antiseptic, as part of Leapfrog’s Partner Advisory Committee.”
Based in Washington, DC, The Leapfrog Group was founded in 2000 with the goal of improving American health care by transparently reporting information people need on medical errors, accidents, and infections. Leapfrog sets standards and publishes ratings of hospitals and ASCs on quality of care and serves as the foremost voice for business leaders advancing excellence in health care. Leapfrog partners advise the Leapfrog Board and management on industry and policy trends and help shape the organization’s long term strategic vision for improving health care quality. The Partners Advisory Committee is a platform for the creation, implementation, and evaluation of initiatives that advance the Leapfrog mission for patient safety and promote a shared accountability for patient safety and well-being.
Since 2004, Nozin has pioneered the use of its Nasal Sanitizer® antiseptic and has helped demonstrate that nasal decolonization reduces infection risk. As reported in numerous published hospital studies, Nozin programs substantially improve patient safety and reduce millions of dollars in healthcare costs.
Visit leapfroggroup.organd Nozin.com for more information.
###
About Nozin
Nozin is the leading brand in nasal decolonization. Nozin NOVA℠ programs and Nozin® Nasal Sanitizer® antiseptic from Global Life Technologies Corp. are empowering healthcare professionals across the country. Designed to improve care, mitigate infection risk and reduce healthcare costs, universal decolonization programs using Nozin® Nasal Sanitizer® deliver clinically supported infection prevention solutions for healthcare facilities.
About The Leapfrog Group
Founded in 2000 by large employers and other purchasers, The Leapfrog Group is a national nonprofit organization driving a movement for giant leaps for patient safety. The flagship Leapfrog Hospital Survey and new Leapfrog Ambulatory Surgery Center (ASC) Survey collect and transparently report hospital and ASC performance, empowering purchasers to find the highest-value care and giving consumers the lifesaving information they need to make informed decisions. The Leapfrog Hospital Safety Grade, Leapfrog's other main initiative, assigns letter grades to hospitals based on their record of patient safety, helping consumers protect themselves and their families from errors, injuries, accidents, and infections. For more, follow us on Twitter and Facebook, and sign up for our newsletter.
Nozin®, Nasal Sanitizer®, and NOVA℠ are trademarks of Global Life Technologies Corp. Leapfrog is a trademark of Leapfrog Group Corporation. All other company and product names may be trademarks of their respective owners.
Stephanie Wight, CURA Strategies, https://curastrategies.com/, 1 301-512-5583, [email protected]
Share this article